Literature DB >> 1732432

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.

J A Talcott1, R D Siegel, R Finberg, L Goldman.   

Abstract

PURPOSE: The study was undertaken to validate a clinical model for predicting the medical risk of cancer patients with fever and neutropenia. PATIENTS AND METHODS: A consecutive sample of 444 cancer patients with fever and neutropenia (granulocyte count less than 500/microL) at two hospitals, a specialized cancer referral center and a university-affiliated general medical hospital, was studied to identify clinical characteristics in the first 24 hours that predict subsequent serious medical complications during the hospital stay. To control for bias, major risk factors and complications were subject to blinded review.
RESULTS: Serious medical complications occurred in 34% of patients with risk factors identified in a prior study, including prior inpatient status (group I), outpatients with a serious independent comorbidity (group II), or uncontrolled cancer (group III), compared with 5% of the remaining patients (group IV) (P less than .000001). Two of the complications in group IV patients were transient asymptomatic hypotension, and the remaining three complications occurred after at least 1 week of progressive medical deterioration. These risk groups were independently significant in stepwise logistic regression analysis. Multiple complications (17%) and death (10%) were common among patients in groups I through III but did not occur in group IV patients.
CONCLUSIONS: This risk assessment model accurately stratified the medical risk of these patients using only clinical information available on the first day of their course. Low-risk patients are an appropriate population in which to study less intensive treatment strategies.

Entities:  

Mesh:

Year:  1992        PMID: 1732432     DOI: 10.1200/JCO.1992.10.2.316

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  84 in total

Review 1.  Colony-stimulating factors for the management of neutropenia in cancer patients.

Authors:  David C Dale
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.

Authors:  James A Talcott; Beow Y Yeap; Jack A Clark; Robert D Siegel; Elizabeth Trice Loggers; Charles Lu; Paul A Godley
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

3.  Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.

Authors:  Ann M Hendricks; Elizabeth Trice Loggers; James A Talcott
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

Review 4.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.

Authors:  Toshiro Mizuno; Noriyuki Katsumata; Hirofumi Mukai; Chikako Shimizu; Masashi Ando; Toru Watanabe
Journal:  Support Care Cancer       Date:  2006-08-29       Impact factor: 3.603

6.  Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center.

Authors:  E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

7.  An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients.

Authors:  A Engel; E Mack; P Kern; W V Kern
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

Review 8.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Mark Holdsworth; Jeff Hanrahan; Bernadette Albanese; Jami Frost
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; J Virizuela; M Antonio; C Font; M Biosca; A Ramchandani; J Martinez-Garcia; J Hernando; J Espinosa; E M de Castro; I Ghanem; C Beato; A Blasco; M Garrido; R Mondéjar; M Á Arcusa; I Aragón; A Manzano; E Sevillano; E Castañón; F Ayala
Journal:  Clin Transl Oncol       Date:  2016-08-15       Impact factor: 3.405

10.  Febrile neutropenia studies in Brazil - treatment and cost management based on analyses of cases.

Authors:  Marcelo Bellesso
Journal:  Rev Bras Hematol Hemoter       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.